首页|Cerebral Embolie Protection during Transcatheter Aortic-Valve Replacement
Cerebral Embolie Protection during Transcatheter Aortic-Valve Replacement
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Massachusetts Medical Soc
BACKGROUND Transcatheter aortic-valve replacement (TAVR) for the treatment of aortic stenosis can lead to embolization of debris. Capture of debris by devices that provide cerebral embolic protection (CEP) may reduce the risk of stroke. METHODS We randomly assigned patients with aortic stenosis in a 1:1 ratio to undergo transfemoral TAVR with CEP (CEP group) or without CEP (control group). The primary end point was stroke within 72 hours after TAVR or before discharge (whichever came first) in the intention-to-treat population. Disabling stroke, death, transient ischemic attack, delirium, major or minor vascular complications at the CEP access site, and acute kidney injury were also assessed. A neurology professional examined all the patients at baseline and after TAVR. RESULTS A total of 3000 patients across North America, Europe, and Australia underwent randomization; 1501 were assigned to the CEP group and 1499 to the control group. A CEP device was successfully deployed in 1406 of the 1489 patients (94.4%) in whom an attempt was made. The incidence of stroke within 72 hours after TAVR or before discharge did not differ significantly between the CEP group and the control group (2.3% vs. 2.9%; difference, -0.6 percentage points; 95% confidence interval, -1.7 to 0.5; P=0.30). Disabling stroke occurred in 0.5% of the patients in the CEP group and in 1.3% of those in the control group. There were no substantial differences between the CEP group and the control group in the percentage of patients who died (0.5% vs. 0.3%); had a stroke, a transient ischemic attack, or delirium (3.1% vs. 3.7%); or had acute kidney injury (0.5% vs. 0.5%). One patient (0.1%) had a vascular complication at the CEP access site. CONCLUSIONS Among patients with aortic stenosis undergoing transfemoral TAVR, the use of CEP did not have a significant effect on the incidence of periprocedural stroke, but on the basis of the 95% confidence interval around this outcome, the results may not rule out a benefit of CEP during TAVR. (Funded by Boston Scientific; PROTECTED TAVR ClinicalTrials.gov number, NCT04149535.)
Samir R. Kapadia、Raj Makkar、Martin Leon、Mohamed Abdel-Wahab、Thomas Waggoner、Steffen Massberg、Wolfgang Rottbauer、Samuel Horr、L ars Sondergaard、Juhana Karha、Robert Gooley、Lowell Satler、Robert C. Stoler、Steven R. Messe、Suzanne J. Baron、Julia Seeger、Susheel Kodali、Amar Krishnaswamy、Vinod H. Thourani、Katherine Harrington、Stuart Pocock、Rodrigo Modolo、Dominic J. Allocco、Ian T. Meredith、Axel Linke、for the PROTECTED TAVR Investigators
展开 >
Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Ave., J2-3, Cleveland, OH
NSTL
Massachusetts Medical Soc
